On 6 Nov 2026, Dr Agarwals Eye Hospital was priced at ₹5,380.00, or 33.9× trailing earnings, against an industry P/E of 47.7×. Sales and net profit grew 21% and 24% a year over 3 years; its ROCE of 16% is the second-highest among the 7 largest Medical Care Facilities peers. Debt is 0.94× equity, and its dividend yield is 0.1%. It is a small-cap company with a market cap of ₹2,600 Cr, ranked 19th of 40 Medical Care Facilities companies by market cap; the shares rose 1.1% over the past year.
- ₹5,391.00
- ₹5,439.00
- ₹5,310.00
- ₹5,395.50
- 756
Health check
- ReturnsIn line
+1.1% over a year, better than 3 of 7 peers.
- Price tagCheaper
P/E 33.9 vs industry 47.7.
- GrowthStrong
Sales +20.7%, profit +23.8% a year over 3 years.
- ProfitabilityAverage
ROCE 16.1% vs peer median 11.9%.
- Balance sheetFair
Debt 0.94× equity, interest covered 8.9×, Piotroski 7 of 9.
- Red flagsNone found
No warning signs in the headline numbers.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹2,600 Cr
- Small cap
- P/E
- 33.9
- Industry 47.7
- Price to book
- 7.51
- Peers 8.06
- Dividend yield
- 0.15%
- ROE
- 25.2%
- Peers 12.8%
- ROCE
- 16.1%
- Peers 11.9%
- Debt to equity
- 0.94
- Debt ₹326 Cr
- EPS (TTM)
- ₹158.78
- Face value ₹10
- OPM (TTM)
- 22.2%
- Net margin 15.3%
- Sales growth
- +22.3%
- Latest quarter vs a year ago
- Profit growth
- +35.5%
- Latest quarter vs a year ago
- Price to sales
- 5.23
- EV/EBITDA 18.1
Strengths and risks
Strengths
- Return on equity of 25.2%.
- Quarterly profit up 35.5% on a year ago.
- Quarterly sales up 22.3% on a year ago.
- P/E of 33.9 against an industry P/E of 47.7.
- Positive operating cash flow in each of the last 4 years.
About Dr Agarwals Eye Hospital
Dr. Agarwal's Eye Hospital Limited engages in the provision of eye care and related services in India, Ghana, Uganda, Kenya, Madagascar, Tanzania, Rwanda, Zambia, Mozambique, and Mauritius. The company, through its hospitals, offers services in the areas of cataract, glaucoma, laser correction, cornea and refractive, retina, squint, corneal ulcer, fungal keratitis, diabetic retinopathy, retinal detachment, nystagmus, ptosis, conjunctivitis, retinopathy…
- Headquarters
- Chennai
- Employees
- 1,356
- Sector
- Healthcare
- ISIN
- INE934C01018
- Website
- dragarwal.com
Price range
- Avg volume (3M)
- 1.7K
- 1-year return
- plus 1.1%
- From 52-week high
- minus 2.2%
Peers · Medical Care Facilities
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| APOLLOHOSPApollo Hospitals Enterprise | 8,446.00 | plus 0.90% | 1,21,441 | 54.0 | 11.45 | 19.2% | 22.5% | 15.4% | 14.8% | 33.3% | 0.24% | plus 7.2% |
| MAXHEALTHMax Healthcare Institute | 934.00 | plus 0.21% | 90,909 | 66.1 | 8.03 | 12.6% | 12.8% | 26.8% | 22.4% | 9.3% | 0.21% | minus 18.1% |
| MANIPALHOSManipal Health Enterprises | 646.70 | minus 1.61% | 85,065 | 133.6 | 9.05 | 9.8% | 9.2% | 17.8% | – | – | 0.00% | minus 3.0% |
| ASTERDMAster DM Quality Care | 713.15 | minus 0.89% | 62,092 | 90.7 | 8.06 | 9.4% | 9.7% | 17.4% | 15.7% | −3.0% | 0.42% | plus 4.5% |
| FORTISFortis Healthcare | 766.90 | minus 6.45% | 57,898 | 55.7 | 5.52 | 11.9% | 10.4% | 22.2% | 13.3% | 20.9% | 0.13% | minus 19.6% |
| NHNarayana Hrudayalaya | 1,903.00 | minus 0.65% | 38,650 | 44.7 | 7.73 | 11.4% | 19.1% | 18.5% | 20.5% | 9.9% | 0.24% | plus 4.7% |
| MEDANTAGlobal Health | 1,387.60 | minus 0.15% | 37,264 | 60.4 | 8.63 | 15.0% | 15.2% | 22.1% | 17.2% | 19.5% | 0.04% | plus 11.2% |
| DRAGARWQDr Agarwals Eye Hospital | 5,380.00 | minus 0.29% | 2,600 | 33.9 | 7.51 | 16.1% | 25.2% | 22.2% | 20.7% | 23.8% | 0.15% | plus 1.1% |
| Median of 7 peers | – | −0.65% | 62,092 | 60.4 | 8.06 | 11.9% | 12.8% | 18.5% | 16.5% | 14.7% | 0.21% | 4.5% |
Quarterly results
| ₹ Cr | Mar 25 | Jun 25 | Sep 25 | Dec 25 | Mar 26 | Jun 26 |
|---|---|---|---|---|---|---|
| 99.8 | 117 | – | 116 | 120 | 143 | |
| – | – | – | – | +20.2% | +22.3% | |
| 68.2 | 79.8 | – | 81.9 | 86.3 | 99.7 | |
| 31.6 | 37.1 | – | 34.4 | 33.7 | 43.3 | |
| 31.6% | 31.8% | – | 29.6% | 28.1% | 30.3% | |
| −0.5 | 0.8 | – | 2.8 | 1.6 | 2 | |
| 2.9 | 4.2 | – | 2 | 2 | 2.8 | |
| 10.2 | 10.6 | – | 11.7 | 12.1 | 11.5 | |
| 18 | 23.2 | – | 23.5 | 21.3 | 31 | |
| 14.5% | 25.6% | – | 26.3% | 23.6% | 24.5% | |
| 16 | 17.3 | – | 17.3 | 16.2 | 23.4 | |
| – | – | – | – | +1.6% | +35.5% | |
| – | 36.72 | 41.04 | 35.76 | 33.60 | 48.38 |
Profit & loss
- Sales CAGR 3Y
- +20.7%
- Profit CAGR 3Y
- +23.8%
- EPS CAGR 3Y
- +23.2%
- ROE
- 25.2%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 267 | 317 | 394 | 470 | |
| – | +18.7% | +24.4% | +19.2% | |
| 190 | 224 | 273 | 322 | |
| 76.7 | 92.6 | 121 | 148 | |
| 28.7% | 29.3% | 30.7% | 31.4% | |
| −0.1 | 3.8 | 1.6 | 1 | |
| 6.8 | 7.1 | 12.4 | 11.8 | |
| 20.2 | 26.6 | 39.5 | 45.6 | |
| −0.2 | −0.4 | 0.2 | 2.4 | |
| 49.4 | 62.3 | 70.7 | 93.6 | |
| 25.3% | 25.5% | 22.7% | 25.1% | |
| 36.9 | 46.4 | 54.7 | 70.1 | |
| – | +25.6% | +17.9% | +28.3% | |
| 78.55 | 98.64 | 116.28 | 147.02 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 4.7 | 4.7 | 4.7 | 4.8 | |
| 109 | 152 | 205 | 341 | |
| 232 | 268 | 333 | 326 | |
| 44.1 | 70.6 | 70.6 | 94 | |
| 390 | 496 | 613 | 766 | |
| 325 | 417 | 507 | 581 | |
| 65.8 | 102 | 142 | 206 | |
| 1 | 1.1 | 1.2 | 1.6 | |
| 27.4 | 32.9 | 22.9 | 95.7 | |
| −29.3 | −56.6 | −60.4 | −118 | |
| 390 | 496 | 613 | 766 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 69.6 | 89.8 | 93.6 | 145 | |
| −70.6 | −70 | −133 | −174 | |
| 0.3 | −14.2 | 16.6 | 24.8 | |
| −0.7 | 5.5 | −22.6 | −3.6 | |
| −70.3 | −71.3 | −103 | −98.4 | |
| −0.7 | 18.5 | −9.3 | 46.8 | |
| −1.4 | −2.6 | −2.4 | −3.1 |
Shareholding pattern
NSE hasn’t returned a shareholding pattern for this company. Institutions hold about 1.8% (Yahoo estimate).
Major shareholders
Filings & events
News
No recent news coverage found.